Who
Pascale Witz
Director
Company insider
Files Form 4 as: Director, Revvity; Director, Regulus Therapeutics; Director, Horizon Therapeutics Public Ltd Co; Director, Tesaro.
In numbers
- Trades disclosed
- 105
- Buys
- 1
- Sells
- 2
- Bought
- $32K
- Sold
- $279K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 1 Jun 2017
- Last trade
- 7 May 2026
- Last filed
- 11 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,650 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,325 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —677 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeutics | SEC FORM 4 Code D | —67,233 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,074 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,338 at $0.00 | filing |
| 30 Apr 2025filed 30 Apr 2025 | Regulus Therapeutics | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 20 May 2024filed 21 May 2024 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —977 at $0.00 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonRVTY · themarketsdaily.com · 19 Oct 2026Revvity (NYSE:RVTY) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.RVTY · dailypolitical.com · 14 Oct 2026Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Revvity Inc. (NYSE:RVTY)RVTY · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Pascale Witz; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.